Slamon Dennis
Known title: DirectorCIK: 0001603265
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 9,510 | $797K | 3/18/2024 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 10,000 | $797K | 3/18/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,190 | $0 | 5/23/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 4,980 | $0 | 5/24/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 122 | $10K | 2/28/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 100 | $8K | 2/28/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,815 | $455K | 2/28/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 45 | $4K | 2/28/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 214 | $17K | 2/28/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 100 | $8K | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.